IGC Pharma (IGC) Asset Writedowns and Impairment (2014 - 2025)
IGC Pharma (IGC) posted quarterly Asset Writedowns and Impairment of $152000.0 for Q1 2025, up 104.66% year-over-year from $74271.2 in Q1 2024, and up 104.66% quarter-over-quarter from -$3.3 million in Q1 2024.
IGC Pharma (IGC) Asset Writedowns and Impairment (2014 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Asset Writedowns and Impairment for 11 consecutive years, with $152000.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Asset Writedowns and Impairment rose 104.66% year-over-year to $152000.0; the TTM figure through Mar 2025 stood at -$3.0 million (up 4.84% YoY), while the FY2025 annual figure was $152000.0, up 63.44% from the prior year.
- Asset Writedowns and Impairment grew to $152000.0 in Q1 2025 per IGC's latest filing, from -$3.3 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $169000.0 in Q1 2021 and bottomed at -$3.3 million in Q1 2024.
- Historically, Asset Writedowns and Impairment has averaged -$611000.0 across 5 years, with a median of $81500.0 in 2021.
- Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment surged 114.24% — and 2024, when it sank 2691.27%.
- IGC Pharma's Asset Writedowns and Impairment stood at $37000.0 in 2021, then sank by 2491.89% to -$885000.0 in 2022, then soared by 114.24% to $126000.0 in 2023, then tumbled by 2691.27% to -$3.3 million in 2024, then soared by 104.66% to $152000.0 in 2025.
- Business Quant data shows IGC's Asset Writedowns and Impairment at $152000.0 in Q1 2025, -$3.3 million in Q1 2024, and $126000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 152,000.00 |
| Mar 31, 2025 | 152,000.00 |
| Mar 31, 2024 | -3.27 Mn |
| Mar 31, 2024 | -3.27 Mn |
| Mar 31, 2023 | 126,000.00 |
| Mar 31, 2023 | 126,000.00 |
| Mar 31, 2022 | -885,000.00 |
| Mar 31, 2022 | -885,000.00 |
| Jun 30, 2021 | 37,000.00 |
| Jun 30, 2021 | 37,000.00 |
| Mar 31, 2021 | 169,000.00 |
| Mar 31, 2021 | 169,000.00 |
| Mar 31, 2020 | 782,000.00 |
| Mar 31, 2020 | 782,000.00 |
| Mar 31, 2019 | -47,000.00 |
| Mar 31, 2019 | -47,000.00 |
| Dec 31, 2018 | 650,000.00 |
| Dec 31, 2018 | 650,000.00 |
| Mar 31, 2017 | -177,993.00 |
| Mar 31, 2017 | -177,993.00 |